Dr. Kelsh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3901 Rainbow Blvd
Kansas City, KS 66160Phone+1 913-588-1304Fax+1 913-588-1310- Is this information wrong?
Education & Training
- University of Kansas School of MedicineResidency, Psychiatry, 1992 - 1996
- University of Kansas School of MedicineResidency, Internal Medicine, 1991 - 1991
- University of Kansas School of MedicineClass of 1991
Certifications & Licensure
- KS State Medical License 1995 - 2024
- American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) Start of enrollment: 2011 Jan 17
- Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy Volunteers Start of enrollment: 2016 Jul 01
- Pharmacokinetic Evaluation of Nalmefene Administered Intranasally to Healthy Volunteers Start of enrollment: 2017 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- A phase 1 randomized, placebo-controlled study to investigate potential interactions between ASP8062, a positive allosteric modulator of the GABAreceptor, and morphine...Mototsugu Ito, Mark Walzer, Mary Beth Blauwet, Anna Spence, Nakyo Heo, Debra Kelsh, Paul Blahunka, Jay Erdman, Mohamad Nour Alsharif, Gerard J Marek> ;Journal of Psychopharmacology. 2023 May 1
- A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder.Mototsugu Ito, Mark Walzer, Mary Beth Blauwet, Anna Spence, Nakyo Heo, Debra Kelsh, Paul Blahunka, Jay Erdman, Mohamad Nour Alsharif, Gerard J Marek> ;Journal of Psychopharmacology. 2023 Feb 1
- 3 citationsOral, intranasal, and intravenous abuse potential of serdexmethylphenidate, a novel prodrug of d-methylphenidate.Megan J Shram, Beatrice Setnik, Lynn Webster, Sven Guenther, Travis C Mickle, Rene Braeckman, Jaroslaw Kanski, Andrea Martin, Debra Kelsh, Bradley D Vince, Andrew C Ba...> ;Current Medical Research and Opinion. 2022 Jul 1
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: